Immunomodulating activity of Agaricus brasiliensis KA21 in mice and in human volunteers

Evidence-based Complementary and Alternative Medicine

Volumn 5, Issue 2, 2008, Pages 205-219

  Liu, Ying ^a   Fukuwatari, Yasushi ^a   Okumura, Ko ^b   Takeda, Kazuyoshi ^b   Ishibashi, Ken Ichi ^c   Furukawa, Mai ^c   Ohno, Naohito ^c   Mori, Kazu ^d   Gao, Ming ^d   Motoi, Masuro ^e  

^a Mibyou Medical Research Center   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e Toei Pharmaceutical Co Ltd   (Japan)

Author keywords

A. brasiliensis; Clinical research; Cold water extract; NK activity; Outdoor cultivated; Safety

Indexed keywords

AGARICUS BRASILIENSIS EXTRACT; CHOLESTEROL; ENDOTOXIN; GLUCOSE; PLANT EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; AGARICUS; AGARICUS BRASILIENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; LEUKOCYTE; LIVER INJURY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SARCOMA; SHOCK;

EID: 44649089445     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nem016     Document Type: Article

References (70)

1. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
2. Mayell M. Maitake extracts and their therapeutic potential. Altern Med Rev 2001;6:48-60.
3. Ventura C. CAM and cell fate targeting: molecular and energetic insights into cell growth and differentiation. Evid Based Complement Alternat Med 2005;2:277-83.
4. Cooper EL. Bioprospecting: a CAM Frontier. Evid Based Complement Alternat Med 2005;2:1-3.
5. Takeda K, Okumura K. CAM and NK cells. Evid Based Complement Alternat Med 2004;1:17-27.
6. Shimazawa M, Chikamatsu S, Morimoto N, Mishima S, Nagai H, Hara H. Neuroprotection by Brazilian green propolis against in vitro and in vivo ischemic neuronal damage. Evid Based Complement Alternat Med 2005;2:201-7.
7. Cooper EL. CAM. eCAM, bioprospecting: the 21st century pyramid. Evid Based Complement Alternat Med 2005;2:125-7.
8. Lindequist U, Timo H, Niedermeyer J, Jülich WD. The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2005;2:285-99.
9. Terasawa K. Evidence-based reconstruction of kampo medicine: Part I - Is kampo CAM? Evid Based Complement Alternat Med 2004;1:11-16.
10. Kaminogawa S, Nanno M. Modulation of immune functions by foods. Evid Based Complement Alternat Med 2004;1:241-50.
11. Atsumi K. is alternative medicine really effective? Alternative Medicine 2000 (in Japanese).
12. Atsumi K. Recommendations of Alternative Medicine. Japan Medical Planning 2000 (in Japanese).
13. Huan SJ, Mau JL. Antioxidant properties of methanolic extracts from Agaricus blazei with various doses of γ-irradiation. Food Sci Technol 2006;39:707-16.
14. Bellini MF, Angeli JPF, Matuo R, Terezan AP, Ribeiro LR, Mantovani MS. Antigenotoxicity of Agaricus blazei mushroom organic and aqueous extracts in chromosomal aberration and cytokinesis block micronucleus assays in CHO-k1 and HTC cells. Toxicol in Vitro 2006;20:355-60.
15. Zhong M, Tai A, Yamamoto I. In vitro augmentation of natural killer activity and interferon-γ production in murine spleen cells with agaricus blazei fruiting body fractions. Biosci Biotechnol Biochem 2005;69:2466-9.
16. Ellertsen LK, Hetland G, Johnson E, Grinde B. Effect of a medicinal extract from Agaricus blazei Murill on gene expression in a human monocyte cell line as examined by microarrays and immuno assays. Int Immunopharmacol 2005;6:133-43.
17. Kobayashi H, Yoshida R, Kanada Y, Fukuda Y, Yagyu T, Inagaki K, et al. Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol 2005;131:527-38.
18. Ker YB, Chen KC, Chyau CC, Chen CC, Guo JH, Hsieh CL, et al. Antioxidant capability of polysaccharides fractionated from submerge-cultured Agaricus blazei mycelia. J Agric Food Chem 2005;53:7052-8.
19. Ohno N, Furukawa M, Miura NN, Adachi Y, Motoi M, Yadomae T. Antitumor beta-glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bulletin 2001;24:820-8.
20. Ohno N, Akanuma AM, Miura NN, Adachi Y, Motoi M. (1-3)-beta-glucan in the fruit bodoes of Agaricus blazei. Pharm Pharmacol Lett 2001;11:87-90.
21. Motoi M, Ishibashi K, Mizukami O, Miura NN, Adachi Y, Ohno N. Anti beta-glucan antibody in cancer patients (preliminary report). Int J Med Mushrooms 2004;6:41-48.
22. Liu Y, Fukuwatari Y, Okumura K, Takeda K, Ohno N, Mori K, et al. Basic and clinical research on immunoregulatory activity of Agaricus blazei. Toho Igaku 2004;20:29-36.
23. Akanuma AM, Yamagishi A, Motoi M, Ohno N. Cloning and characterization of polyphenoloxidase DNA from Agaricus brasiliensis S. Wasser et al. (Agaricomycetideae). Int J Med Mushrooms 2006;8:67-76.
24. Hashimoto S, Akanuma AM, Motoi M, Imai N, Rodrignes CA, et al. Effect of culture conditions on chemical composition and biological activities of Agaricus braziliensis. Int J Med Mushrooms, in press.
25. Furukawa M, Miura NN, Adachi Y, Motoi M, Ohno N. Effect of Agaricus brasiliensis on Murine Diabetic Model C57Bl/Ksj-db/db. Int J Med Mushrooms 2006;8:115-28.
26. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. J Clin oncology 2006;36:808-10.
27. Christine KC, Mark AR, Jay Olshansky S. The price of success: health care in an aging society. Health aff 2002;21:87-99.
28. Kaneko H, Nakanishi K. Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical Ginseng, Korean red Ginseng: specifically, its anti-stress action for prevention of disease. J Pharmacol Sci 2004;95:158-62.
29. Iino K, Ohno N, Suzuki I, Sato K, Oikawa S, Yadomae T. Structure-function relationship of antitumor beta-1,3-glucan obtained from matted mycelium of cultured Grifola frondosa. Chem Pharm Bull 1985;33:4950-6.
30. Ohno N, Adachi Y, Suzuki I, Oikawa S, Sato K, Ohsawa M, et al. Antitumor activity of a beta-1,3-glucan obtained from liquid cultured mycelium of Grifola frondosa. J Pharmacobiodyn 1986;9:861-4.
31. Takeyama T, Suzuki I, Ohno N, Oikawa S, Sato K, Ohsawa M, et al. Host-mediated antitumor effect of grifolan NMF-5N, a polysaccharide obtained from Grifola frondosa. J Pharmacobiodyn 1987;10:644-51.
32. Suzuki I, Takeyama T, Ohno N, Oikawa S, Sato K, Suzuki Y, et al. Antitumor effect of polysaccharide grifolan NMF-5N on syngeneic tumor in mice. J Pharmacobiodyn 1987;10:72-7.
33. Kodama N, Asakawa A, Inui A, Masuda Y, Nanba H. Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncol Rep 2005;13:497-502.
34. Kodama N, Komuta K, Nanba H. Effect of maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J Med Food 2003;6:371-7.
35. Harada N, Kodama N, Nanba H. Relationship between dendritic cells and the D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice. Cancer Lett 2003;192:181-7.
36. Kodama N, Komuta K, Nanba H. Can maitake MD-fraction aid cancer patients? Altern Med Rev 2002;7:236-9.
37. Inoue A, Kodama N, Nanba H. Effect of maitake (Grifola frondosa) D-fraction on the control of the T lymph node Th-1/Th-2 proportion. Biol Pharm Bull 2002;25:536-40.
38. Masaki K, Hirotake K. Delayed cell cycle progression and apoptosis induced by hemicellulase-treated Agaricus blazei. Evid Based Complement Alternat Med 2006; in press, available on-line.
39. Kasai HL, He M, Kawamura M, Yang PT, Deng XW, Munkanta M, et al. IL-12 production induced by Agaricus blazei fraction H (ABH) involves toll-like receptor (TLR). Evid Based Complement Altern Med 2004;1:259-67.
40. Inagaki N, Shibata T, Itoh T, Suzuki T, Tanaka H, Nakamura T, et al. Inhibition of IgE-dependent mouse triphasic cutaneous reaction by a boiling water fraction separated from mycelium of Phellinus linteus. Evid Based Complement Altern Med 2005;2:369-74.
41. Al-Fatimi MAA, Jülich W-D, Jansen R, Lindequist U. Bioactive components of the traditionally used mushroom podaxis pistillaris. Evid Based Complement Altern Med 2006;3:87-92.
42. Andersson HC, Hajslova J, Schulzova V, Panovska Z, Hajkova L, Gry J. Agaritine content in processed foods containing the cultivated mushroom (Agaricus bisporus) on the Nordic and the Czech market. J Food Addit Contam 1999;16:439-46.
43. Schulzova V, Hajslova J, Peroutka R, Gry J, Andersson HC. Influence of storage and household processing on the agaritine content of the cultivated Agaricus mushroom. Food Addit Contam 2002;19:853-62.
44. Friederich U, Fischer B, Luthy J, Hann D, Schlatter C, Wurgler FE. The mutagenic activity of agaritine - a constituent of the cultivated mushroom Agaricus bisporus - and its derivatives detected with the Salmonella/mammalian microsome assay (Ames Test). Z Lebensm Unters Forsch 1986;183:85-9.
45. Papaparaskeva C, Ioannides C, Walker R. Agaritine does not mediate the mutagenicity of the edible mushroom Agaricus bisporus. Mutagenesis 1991;6:213-7.
46. Toth B, Gannett P, Rogan E, Williamson J. Bacterial mutagenicity of extracts of the baked and raw Agaricus bisporus mushroom. In Vivo 1992;6:487-90.
47. Nagaokaa MH, Nagaoka H, Kondo K, Akiyama H, Maitani T. Measurement of a genotoxic hydrazine, agaritine, and its derivatives by HPLC with fluorescence derivatization in the agaricus mushroom and its products. Chem Pharm Bull 2006;54:922-4.
48. Hajslova J, Hajkova L, Schulzova V, Frandsen H, Gry J, Andersson HC. Stability of agaritine - a natural toxicant of Agaricus mushrooms. Food Addit Contam 2002;19:1028-33.
49. Toth B. Carcinogenic fungal hydrazines. In Vivo 1991;5:95-100.
50. Toth B, Sornson H. Lack of carcinogenicity of agaritine by subcutaneous administration in mice. Mycopathologia 1984;85:75-9.
51. Toth B, Taylor J, Mattson B, Gannett P. Tumor induction by 4-(methyl)benzenediazonium sulfate in mice. In vivo 1989;3:17-22.
52. Stamets P. Notes on nutritional properties of culinary-medicinal mushrooms. Int J Med Mushrooms 2005;7:103-10.
53. Ohno N, Yadomae T. Mitogenic substances of Bupleuri radix, in traditional herbal medicines for modern times, Bupleurum species, scientific evaluation and clinical applications. In: Sheng-Li (ed). CRC Taylor & Francis, 2006, 159-76.
54. Izumi S, Ohno N, Kawakita T, Nomoto K, Yadomae T. Wide range of molecular weight distribution of mitogenic substance(s) in the hot water extract of a Chinese herbal medicine, Bupleurum chinense. Biol Pharm Bull 1997;20:759-64.
55. Ohtsu S, Izumi S, Iwanaga S, Ohno N, Yadomae T. Analysis of mitogenic substances in Bupleurum chinense by ESR spectroscopy. Biol Pharm Bull 1997;20:97-100.
56. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223-46.
57. Okamoto M, Hasegawa Y, Hara T, Hashimoto N, Imaizumi K, Shimokata K, et al. T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest 2005;128:4030-5.
58. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
59. Sarangi I, Ghosh D, Bhutia SK, Mallick SK, Maiti TK. Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans. Int Immunopharmacol 2006;6:1287-97.
60. Kim GY, Lee JY, Lee JO, Ryu CH, Choi BT, Jeong YK, et al. Partial characterization and immunostimulatory effect of a novel polysaccharide-protein complex extracted from Phellinus linteus. Biosci Biotechnol Biochem 2006;70:1218-26.
61. Ahn WS, Kim DJ, Chae GT, Lee JM, Bae SM, Sin JI, et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer 2004;14:589-94.
62. Kaneno R, Fontanari LM, Santos SA, Di Stasi LC, Rodrigues FE, Eira AF. Effects of extracts from Brazilian sun-mushroom (Agaricus blazei) on the NK activity and lymphoproliferative responsiveness of Ehrlich tumor-bearing mice. Food Chem Toxicol 2004;42:909-16.
63. Fujimiya Y, Suzuki Y, Oshiman K, Kobori H, Moriguchi K, Nakashima H, et al. Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother 1998;46:147-59.
64. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45:253-85.
65. Musana AK, Wilke RA. Gene-based drug prescribing: clinical implications of the cytochrome P450 genes. WMJ 2005;104:61-6.
66. Netea MG, Gow NA, Munro CA, Bates S, Collins C, Ferwerda G, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006;116:1642-50.
67. Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006;6:33-43.
68. Saijo S, Fujikado N, Furuta T, Chung S, Kotaki H, Seki K, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not Candida albicans. Nat Immunol 2007;8:39-46.
69. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005;33:638-44.
70. Mullighan CG, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002;99:3524-9.